Tocilizumab in Coronavirus Disease 2019: Give It Time!
Clin Infect Dis
.
2021 Dec 16;73(12):2368-2369.
doi: 10.1093/cid/ciab081.
Authors
Quentin Richier
1
2
,
Léo Plaçais
3
4
,
Karine Lacombe
1
4
,
Olivier Hermine
2
3
5
Affiliations
1
Department of Infectious Diseases, Saint Antoine Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France.
2
University of Paris, Paris, France.
3
Department of Hematology, Necker Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France.
4
Sorbonne University, Paris, France.
5
Imagine Institute, Inserm U1163, Paris, France.
PMID:
33515253
PMCID:
PMC7929041
DOI:
10.1093/cid/ciab081
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Substances
Antibodies, Monoclonal, Humanized
tocilizumab